Skip to main content
Publications
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist. 2025 Mar 10;30(3):oyae289. doi: 10.1093/oncolo/oyae289
Tam S, Neslund-Dudas C, Barrett AM, Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis. Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Nussbaumer-Streit B, Greenblatt A, Kaminski-Hartenthaler A, Van Noord MG, Forneris CA, Morgan LC, Gaynes BN, Wipplinger J, Lux LJ, Winkler D, Gartlehner G. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2019 Jun 17;6(6):CD011271. doi: 10.1002/14651858.CD011271.pub3
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257
Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, Clar C, Germano R, Lunn HR, Frost G, Rees K. Whole grain cereals for the primary or secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD005051. doi: 10.1002/14651858.CD005051.pub3
Forneris CA, Nussbaumer B, Kaminski-Hartenthaler A, Morgan LC, Gaynes BN, Sonis JH, Greenblatt A, Wipplinger J, Lux LJ, Winkler D, Van Noord MG, Hofmann J, Gartlehner G. Psychological therapies for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2015 Nov 11;11(11):CV011270. doi: 10.1002/14651858.CD011270.pub2
Kaminski-Hartenthaler A, Nussbaumer B, Forneris CA, Morgan LC, Gaynes BN, Sonis JH, Greenblatt A, Wipplinger J, Lux LJ, Winkler D, Van Noord MG, Hofmann J, Gartlehner G. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2015 Nov 11;11(11):CD011271. doi: 10.1002/14651858.CD011271.pub2
Gartlehner G, Nussbaumer B, Gaynes BN, Forneris CA, Morgan LC, Kaminski-Hartenthaler A, Greenblatt A, Wipplinger J, Lux LJ, Sonis JH, Hofmann J, Van Noord MG, Winkler D. Second-generation antidepressants for preventing seasonal affective disorder in adults. Cochrane Database Syst Rev. 2015 Nov 8;(11):CD1101126. doi: 10.1002/14651858.CD011268.pub2
Nussbaumer B, Kaminski-Hartenthaler A, Forneris CA, Morgan LC, Sonis JH, Gaynes BN, Greenblatt A, Wipplinger J, Lux LJ, Winkler D, Van Noord MG, Hofmann J, Gartlehner G. Light therapy for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2015 Nov 8;(11):CD011269. doi: 10.1002/14651858.CD011269.pub2